3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Gemina Laboratories's 3-Year ROIIC % for the quarter that ended in Jan. 2025 was 34.99%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Gemina Laboratories's 3-Year ROIIC % or its related term are showing as below:
GLABF's 3-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -4.82
vs GLABF: 34.99
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Gemina Laboratories 3-Year ROIIC % Related Terms
Gemina Laboratories 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Gemina Laboratories's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLABF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Gemina Laboratories's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gemina Laboratories 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gemina Laboratories's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Gemina Laboratories's 3-Year ROIIC % falls into.
Gemina Laboratories's 3-Year ROIIC % for the quarter that ended in Jan. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.719 (Jan. 2025) - -3.751 (Jan. 2022) )
/
( 1.688 (Jan. 2025) - 0.063 (Jan. 2022) )
=
1.032
/
1.625
=
63.51%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Gemina Laboratories (GLABF) has a 3-Year ROIIC % of 34.99 as of Jan. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gemina Laboratories and its competitors. This is near median its historical median of 34.99. Over the past decade, Gemina Laboratories' 3-Year ROIIC % has ranged from 34.99 to 34.99.
Is Gemina Laboratories' 3-Year ROIIC % too high?
Gemina Laboratories' current 3-Year ROIIC % of 34.99 is near median its 10-year median of 34.99. Over the past 10 years, this metric has ranged from a low of 34.99 to a high of 34.99.
How does Gemina Laboratories' 3-Year ROIIC % compare to VRTX and REGN?
Gemina Laboratories' 3-Year ROIIC % of 34.99 can be compared against companies in the Biotechnology industry. Historically, Gemina Laboratories' own 3-Year ROIIC % has ranged from 34.99 to 34.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current 3-Year ROIIC % is 34.99, which is near median its own 10-year median of 34.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current 3-Year ROIIC % of 34.99. The current 3-Year ROIIC % is 34.99, which is near median its 10-year median of 34.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current 3-Year ROIIC % is 34.99 as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLABF has been successfully added to your 